|
|
Article: Allergan Introduces New Fast-Acting Treatment for Itch Associated with Allergic Conjunctivitis.
- Article from:
- PR Newswire
- Article date:
- April 7, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Over 20 Million Americans Affected by Seasonal Eye Allergies
IRVINE, Calif., March 1 /PRNewswire/ --
The availability of ALOCRIL(TM) (nedocromil sodium ophthalmic solution) 2%, an effective topical allergy treatment for itch associated with allergic conjunctivitis, was announced by Allergan, Inc. (NYSE: AGN) today. The U.S. Food and Drug Administration (FDA) approved ALOCRIL(TM) in December 1999. Allergic conjunctivitis sufferers outside of the United States have reaped the benefits from nedocromil sodium 2% for a number of years where it is one of the leading ocular allergy medicines.
According to the American Academy of Ophthalmology (AAO), ...